DK1545587T3 - Lactoferrinsammensætninger og fremgangsmåder til behandling af diabetiske sår - Google Patents
Lactoferrinsammensætninger og fremgangsmåder til behandling af diabetiske sårInfo
- Publication number
- DK1545587T3 DK1545587T3 DK03752398.2T DK03752398T DK1545587T3 DK 1545587 T3 DK1545587 T3 DK 1545587T3 DK 03752398 T DK03752398 T DK 03752398T DK 1545587 T3 DK1545587 T3 DK 1545587T3
- Authority
- DK
- Denmark
- Prior art keywords
- treatment
- methods
- diabetic wounds
- lactoferrin compositions
- lactoferrin
- Prior art date
Links
- 102000010445 Lactoferrin Human genes 0.000 title abstract 2
- 108010063045 Lactoferrin Proteins 0.000 title abstract 2
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 title abstract 2
- 229940078795 lactoferrin Drugs 0.000 title abstract 2
- 235000021242 lactoferrin Nutrition 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 206010052428 Wound Diseases 0.000 title 1
- 208000027418 Wounds and injury Diseases 0.000 title 1
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 206010072170 Skin wound Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Materials Engineering (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41098102P | 2002-09-16 | 2002-09-16 | |
| PCT/US2003/029069 WO2004024180A1 (en) | 2002-09-16 | 2003-09-16 | Lactoferrin compositions and methods of wound treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1545587T3 true DK1545587T3 (da) | 2011-05-09 |
Family
ID=31994228
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK03752398.2T DK1545587T3 (da) | 2002-09-16 | 2003-09-16 | Lactoferrinsammensætninger og fremgangsmåder til behandling af diabetiske sår |
| DK10014943.4T DK2298338T3 (da) | 2002-09-16 | 2003-09-16 | Lactoferrin-sammensætninger og fremgangsmåder til behandling af hudsår |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10014943.4T DK2298338T3 (da) | 2002-09-16 | 2003-09-16 | Lactoferrin-sammensætninger og fremgangsmåder til behandling af hudsår |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US7524814B2 (enExample) |
| EP (2) | EP1545587B1 (enExample) |
| JP (1) | JP4516844B2 (enExample) |
| CN (1) | CN1694720A (enExample) |
| AT (1) | ATE497778T1 (enExample) |
| AU (2) | AU2003270690B2 (enExample) |
| CA (1) | CA2499014A1 (enExample) |
| DE (1) | DE60335997D1 (enExample) |
| DK (2) | DK1545587T3 (enExample) |
| ES (1) | ES2358645T3 (enExample) |
| SI (2) | SI2298338T1 (enExample) |
| WO (1) | WO2004024180A1 (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6399570B1 (en) * | 1999-02-05 | 2002-06-04 | Agennix, Inc. | Antimicrobial/endotoxin neutralizing polypeptide |
| WO2003094952A1 (en) * | 2002-05-10 | 2003-11-20 | Agennix Incorporated | Intratumorally administered lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases |
| AU2003233583A1 (en) * | 2002-05-24 | 2003-12-12 | Agennix Incorporated | Oral lactoferrin in the treatment of respiratory disorders |
| SI2298338T1 (sl) * | 2002-09-16 | 2012-11-30 | Agennix Inc | Laktoferinski sestavki in postopki za zdravljenjekožnih ran |
| EP1581243A4 (en) * | 2002-12-06 | 2008-01-02 | Agennix Inc | ORAL LACTOFERRIN FOR SEPSIS TREATMENT |
| AU2003296447A1 (en) * | 2002-12-10 | 2004-06-30 | Agennix Incorporated | Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease |
| AU2004289170B2 (en) * | 2003-06-06 | 2009-12-17 | Agennix Incorporated | Lactoferrin as an adjuvant in cancer vaccines |
| WO2005018542A2 (en) * | 2003-07-10 | 2005-03-03 | Agennix Incorporated | Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects |
| AR049384A1 (es) | 2004-05-24 | 2006-07-26 | Glaxo Group Ltd | Derivados de purina |
| AU2005277404A1 (en) * | 2004-08-20 | 2006-03-02 | Smithkline Beecham Corporation | Methods of healing wounds by administering human IL-18 |
| US7183381B2 (en) * | 2004-10-26 | 2007-02-27 | Agennix, Inc. | Composition of lactoferrin related peptides and uses thereof |
| US8263105B2 (en) * | 2004-12-01 | 2012-09-11 | Tyco Healthcare Group Lp | Biomaterial drug delivery and surface modification compositions |
| ITRM20040638A1 (it) | 2004-12-24 | 2005-03-24 | Advance Holdings Ltd | Gel piastrinico semisintetico e metodo per la sua preparazione. |
| US20060240116A1 (en) * | 2005-04-22 | 2006-10-26 | David Jolley | Bioactive factors in wound healing topical compositions and methods |
| GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
| WO2007022537A2 (en) * | 2005-08-19 | 2007-02-22 | Agennix Incorporated | Use of lactoferrin as a chemokine and a chemotactic modulator |
| US20070059300A1 (en) * | 2005-09-12 | 2007-03-15 | Zoltan Laboratories Llc | Compounds and compositions to control abnormal cell growth |
| AU2006318655B2 (en) * | 2005-11-18 | 2013-03-28 | Glanbia Nutritionals (Ireland) Ltd. | Compositions for disrupting and inhibiting reconstitution of wound biofilm |
| US20070179084A1 (en) * | 2006-01-30 | 2007-08-02 | Nation Chiao Tung University | Process for reducing the concentration of blood glucose in a diabetic patient |
| DE602006010656D1 (de) * | 2006-02-02 | 2010-01-07 | Euro Celtique Sa | Hydrogel für Wundbehandlung |
| EP1993592A4 (en) * | 2006-02-21 | 2011-11-16 | Ventria Bioscience | COMPOSITIONS WITH LACTOFERRIN AND METHOD FOR USE THAT TO AIM IN THE GROWTH OF SKIN CELLS |
| CN106139124A (zh) * | 2006-07-03 | 2016-11-23 | 让-保罗·佩罗丹 | 抗菌剂组合物及其用途 |
| GB0616580D0 (en) * | 2006-08-21 | 2006-09-27 | Novathera Ltd | Composite material |
| CA2663417A1 (en) | 2006-09-13 | 2008-03-20 | Southeastern Medical Technologies, Llc | Methods and compositions for sealing and adhering biological tissues and medical uses thereof |
| US10143694B2 (en) * | 2006-10-27 | 2018-12-04 | Matthew H. Kopacki | Advanced formulations and therapies for treating hard-to-heal wounds |
| AR065803A1 (es) * | 2007-03-23 | 2009-07-01 | Smithkline Beecham Corp | Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento |
| WO2009123720A2 (en) * | 2008-04-01 | 2009-10-08 | Southeastern Medical Technologies, Llc | Methods and compositions for medical articles produced from proteinaceous compounds |
| EP2141242A1 (en) * | 2008-07-04 | 2010-01-06 | Universität des Saarlandes | Synthetic pathway enzymes for the production of Argyrins |
| US8614189B2 (en) * | 2008-09-24 | 2013-12-24 | University Of Connecticut | Carbon nanotube composite scaffolds for bone tissue engineering |
| US20110015587A1 (en) * | 2009-07-14 | 2011-01-20 | Tumey David M | Irrigation Device and Method Using Same |
| JP2011020973A (ja) * | 2009-07-17 | 2011-02-03 | Nrl Pharma Inc | 難治性の皮膚潰瘍治療用の医薬組成物、及び、皮膚潰瘍予防用化粧料 |
| RU2012126140A (ru) * | 2009-11-25 | 2013-12-27 | Нестек С.А. | Питательные композиции, включающие высокобелковый компонент и экзогенные нуклеотиды |
| US8545927B2 (en) | 2010-05-10 | 2013-10-01 | University Of Connecticut | Lactoferrin-based biomaterials for tissue regeneration and drug delivery |
| IN2013CN00089A (enExample) * | 2010-07-01 | 2015-07-03 | Holden Brien Vision Inst | |
| US10279007B2 (en) | 2010-11-15 | 2019-05-07 | Oxygenetix Institute, Inc. | Topical treatment method for healing wounds, disinfecting, covering and concealing the wound until healing occurs |
| US20120171231A1 (en) * | 2010-12-29 | 2012-07-05 | Anja Wittke | Use of nutritional compositions including lactoferrin in stimulating immune cells |
| WO2012102100A1 (ja) * | 2011-01-26 | 2012-08-02 | 雪印メグミルク株式会社 | 感覚改善剤 |
| CA2826192A1 (en) | 2011-01-31 | 2012-08-09 | The Government Of The United States, As Represented By The Secretary Of The Army | Methods and compositions for treating bacterial infections with iron chelators |
| CN103747814B (zh) * | 2011-08-31 | 2017-11-28 | 凯希特许有限公司 | 减压治疗与清创系统以及方法 |
| CN109260465A (zh) * | 2012-11-14 | 2019-01-25 | 史密夫和内修公司 | 稳定的嗜热菌蛋白酶水凝胶 |
| MX2015013244A (es) | 2013-03-15 | 2016-04-15 | Smith & Nephew Inc | Pelicula soluble formadora de gel para suministrar agentes activos. |
| JP6275955B2 (ja) * | 2013-04-25 | 2018-02-07 | 松尾 敏郎 | 塩化マグネシウムを摂取する人を除いた生物の細胞の活性化方法 |
| CZ308554B6 (cs) * | 2013-10-21 | 2020-11-25 | Univerzita Tomáše Bati ve Zlíně | Hydrogelová kosmetická nebo farmaceutická kompozice s účinnějším působením v ní obsažených biologicky aktivních látek z hlediska antimikrobiálních účinků |
| KR20170086019A (ko) | 2014-09-24 | 2017-07-25 | 이스티튜토 프로필라티코 이 파르마씨유티코 칸디올리 & 씨. 에스.피.에이. | 감염증 및 염증의 예방 및/또는 치료에 유용한 조성물 |
| RU2658707C1 (ru) * | 2016-12-28 | 2018-06-22 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Способ восстановления кожного покрова |
| US20200024329A1 (en) * | 2018-07-17 | 2020-01-23 | Bradley G. Thompson | Methods for regulating endogenous production of lactoferrin and sub-peptides thereof |
| EP3845218A4 (en) * | 2018-07-31 | 2022-05-04 | Lemonex Inc. | PHARMACEUTICAL COMPOSITION FOR WOUND HEALING |
| US20220016220A1 (en) * | 2018-12-11 | 2022-01-20 | Universita' Degli Studi Di Salerno | Composition for the treatment of skin lesions |
| CN110075054A (zh) * | 2019-06-06 | 2019-08-02 | 山东天源人乳库科技发展有限公司 | 一种来源于人乳的人源性生长因子修复制剂及其制备方法 |
| BE1027357B1 (nl) * | 2019-06-12 | 2021-01-18 | Vanlommel Maria Kristel | Voedingssupplement voor versnelde genezing |
| CN110680949B (zh) * | 2019-10-18 | 2021-06-29 | 中山大学 | 一种基于母乳的创伤敷料的制备方法和应用 |
| UY39909A (es) * | 2021-08-23 | 2023-03-31 | Lactea Therapeutics Llc | Composiciones de lactoferrina y métodos de uso |
| CN113576938B (zh) * | 2021-08-26 | 2022-07-08 | 广东丸美生物技术股份有限公司 | 一种口腔护理组合物及其应用 |
| US20240165297A1 (en) * | 2022-08-19 | 2024-05-23 | Philip Neil MacPherson | Hydrogel delivery matrix |
| CN116421775A (zh) * | 2023-04-21 | 2023-07-14 | 青岛优瑞达生物科技有限公司 | 一种乳铁蛋白凝胶敷料、制备方法和应用 |
| CN116251224B (zh) * | 2023-05-16 | 2023-09-12 | 江苏正大天创生物工程有限公司 | 一种乳铁蛋白凝胶敷料及其应用 |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US4788488A (en) * | 1986-10-14 | 1988-11-29 | Drexelbrook Controls, Inc. | Continuous condition sensing system |
| US4783488A (en) * | 1987-01-31 | 1988-11-08 | Bausch & Lomb Incorporated | Contact lens wetting solution |
| US4977137B1 (en) * | 1987-06-03 | 1994-06-28 | Baylor College Medicine | Lactoferrin as a dietary ingredient promoting the growth of the gastrointestinal tract |
| US5457093A (en) | 1987-09-18 | 1995-10-10 | Ethicon, Inc. | Gel formulations containing growth factors |
| US5705485A (en) * | 1987-09-18 | 1998-01-06 | Ethicon, Inc. | Gel formulations containing growth factors |
| US5284760A (en) | 1989-04-03 | 1994-02-08 | Feinstone Stephen M | Techniques for producing site-directed mutagenesis of cloned DNA |
| US5849881A (en) * | 1989-05-05 | 1998-12-15 | Baylor College Medicine | Production of recombinant lactoferrin and lactoferrin polypeptides using cDNA sequences in various organisms |
| IL94183A (en) * | 1989-05-05 | 2003-09-17 | Baylor College Medicine | cDNA SEQUENCE CODING FOR HUMAN LACTOFERRIN PROTEIN OR PORTION THEREOF AND LACTOFERRIN PROTEIN PRODUCED FROM SAID SEQUENCE |
| US6100054A (en) | 1989-05-05 | 2000-08-08 | Baylor College Of Medicine | Production for recombinant lactoferrin and lactoferrin polypeptides using DNA sequences in various organisms |
| US5571691A (en) | 1989-05-05 | 1996-11-05 | Baylor College Of Medicine | Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms |
| US5766939A (en) * | 1989-05-05 | 1998-06-16 | Baylor College Of Medicine | Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms |
| US5571697A (en) | 1989-05-05 | 1996-11-05 | Baylor College Of Medicine Texas Medical Center | Expression of processed recombinant lactoferrin and lactoferrin polypeptide fragments from a fusion product in Aspergillus |
| US5198419A (en) * | 1989-12-08 | 1993-03-30 | Immuno Japan Inc. | Formulated medicines for enhancing the efficacy of beta-lactam antibiotics in prophylaxis and treatment against infectious disease due to pathogenic bacteria |
| WO1991010437A1 (en) * | 1990-01-12 | 1991-07-25 | New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery | Methods of enhancing wound healing and tissue repair |
| US5220007A (en) | 1990-02-15 | 1993-06-15 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of RNA and production of encoded polypeptides |
| US5149797A (en) | 1990-02-15 | 1992-09-22 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of rna and production of encoded polypeptides |
| US6066469A (en) | 1990-03-08 | 2000-05-23 | Ferro Dynamics, Inc. | Cloning, expression, and uses of human lactoferrin |
| GB2248842A (en) | 1990-10-16 | 1992-04-22 | American Cyanamid Co | Film-forming polymer compositions |
| EP0579830B1 (en) * | 1990-11-13 | 1997-02-05 | Santen Pharmaceutical Co., Ltd. | Therapeutic agent for corneal lesion |
| CA2110899C (en) | 1991-06-21 | 2006-08-08 | Jacob G. Michael | Orally administrable therapeutic proteins and method of making |
| WO1993013216A1 (en) | 1991-12-24 | 1993-07-08 | The President And Fellows Of Harvard College | Site-directed mutagenesis of dna |
| DE69322896T2 (de) * | 1992-03-02 | 1999-05-27 | Immuno Japan Inc., Tokio/Tokyo | Verwendung von Proteinen der Transferrin/Lactoferrin-Familie zur Stimulation des Immunsystems |
| DE4208552A1 (de) * | 1992-03-17 | 1993-09-23 | Liedtke Pharmed Gmbh | Topische arzneiformen mit insulin |
| WO1993020826A1 (fr) * | 1992-04-10 | 1993-10-28 | Vsesojuzny Nauchno-Issledovatelsky Institut Meditsinskikh Polimerov | Composition pharmaceutique |
| ZA932568B (en) * | 1992-04-24 | 1993-11-12 | Baylor College Midecine A Non | Production of recombinant human lactoferrin |
| US5389514A (en) | 1992-08-28 | 1995-02-14 | Fox Chase Cancer Center | Method for specifically altering the nucleotide sequence of RNA |
| US5358706A (en) | 1992-09-30 | 1994-10-25 | Union Carbide Chemicals & Plastics Technology Corporation | Muco-adhesive polymers |
| JPH07196529A (ja) * | 1993-12-29 | 1995-08-01 | Morinaga Milk Ind Co Ltd | 創傷治癒剤、化粧料および養毛剤 |
| JPH09509165A (ja) | 1994-02-16 | 1997-09-16 | ファーミング ベスローテン フェンノートシャップ | ミルクからのラクトフェリンの分離 |
| JP3746081B2 (ja) | 1994-02-24 | 2006-02-15 | 森永乳業株式会社 | 動物皮膚病治療剤 |
| US5827874A (en) * | 1995-05-05 | 1998-10-27 | Meyer; Hans | Methods of treating pain and inflammation with proline |
| US20020016289A1 (en) * | 1995-06-01 | 2002-02-07 | Orla M. Conneely | Methods for treatment and prevention of helicobacter pylori infection using lactoferrin |
| US5834424A (en) * | 1995-07-12 | 1998-11-10 | Gambit International Limited | Use of lactoferrin for therapy of acute of chronic infectious diseases by the intracellular gram-positive pathogens streptococcus pyogenes and staphylococcus aureus |
| US5789166A (en) | 1995-12-08 | 1998-08-04 | Stratagene | Circular site-directed mutagenesis |
| US6111081A (en) * | 1996-05-31 | 2000-08-29 | Baylor College Of Medicine | Lactoferrin variants and uses thereof |
| GB2321191B (en) | 1997-01-17 | 2000-09-27 | Johnson & Johnson Medical | Peptides for use in wound treatment |
| AU6307698A (en) | 1997-02-03 | 1998-08-25 | Pharming Bv | Useful properties of human lactoferrin and variants thereof |
| CN1262625A (zh) * | 1997-04-10 | 2000-08-09 | 阿吉尼克斯股份有限公司 | 乳铁蛋白在治疗过敏原诱发疾病中的应用 |
| JP3856908B2 (ja) * | 1997-06-06 | 2006-12-13 | 田辺製薬株式会社 | 褥瘡及び／又は創傷治療剤 |
| US6399570B1 (en) * | 1999-02-05 | 2002-06-04 | Agennix, Inc. | Antimicrobial/endotoxin neutralizing polypeptide |
| US6432415B1 (en) * | 1999-12-17 | 2002-08-13 | Axrix Laboratories, Inc. | Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces |
| RU2165769C1 (ru) | 2000-07-13 | 2001-04-27 | Якубовская Раиса Ивановна | Антибактериальный, антиоксидантный, иммуномодулирующий и антиканцерогенный препарат и способ его применения |
| ES2384099T3 (es) | 2001-06-13 | 2012-06-29 | The University Of Sydney | Proteína C para cicatrización de heridas |
| WO2003094952A1 (en) * | 2002-05-10 | 2003-11-20 | Agennix Incorporated | Intratumorally administered lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases |
| AU2003233583A1 (en) * | 2002-05-24 | 2003-12-12 | Agennix Incorporated | Oral lactoferrin in the treatment of respiratory disorders |
| SI2298338T1 (sl) * | 2002-09-16 | 2012-11-30 | Agennix Inc | Laktoferinski sestavki in postopki za zdravljenjekožnih ran |
| AU2003291206A1 (en) | 2002-12-04 | 2004-06-23 | Agennix Incorporated | Lactoferrin in the reduction of circulating cholesterol, vascular inflammation, atherosclerosis and cardiovascular disease |
| EP1581243A4 (en) | 2002-12-06 | 2008-01-02 | Agennix Inc | ORAL LACTOFERRIN FOR SEPSIS TREATMENT |
| AU2003296447A1 (en) | 2002-12-10 | 2004-06-30 | Agennix Incorporated | Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease |
| AU2003293500A1 (en) * | 2002-12-12 | 2004-07-09 | Agennix Incorporated | Lactoferrin in the reduction of pain |
| US7034126B2 (en) | 2003-05-14 | 2006-04-25 | Agennix, Inc. | Lactoferrin in the treatment of diabetes mellitus |
| AU2004289170B2 (en) | 2003-06-06 | 2009-12-17 | Agennix Incorporated | Lactoferrin as an adjuvant in cancer vaccines |
| WO2005018542A2 (en) * | 2003-07-10 | 2005-03-03 | Agennix Incorporated | Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects |
-
2003
- 2003-09-16 SI SI200332199T patent/SI2298338T1/sl unknown
- 2003-09-16 DK DK03752398.2T patent/DK1545587T3/da active
- 2003-09-16 DK DK10014943.4T patent/DK2298338T3/da active
- 2003-09-16 AU AU2003270690A patent/AU2003270690B2/en not_active Ceased
- 2003-09-16 SI SI200331990T patent/SI1545587T1/sl unknown
- 2003-09-16 US US10/663,258 patent/US7524814B2/en not_active Expired - Fee Related
- 2003-09-16 CA CA002499014A patent/CA2499014A1/en not_active Abandoned
- 2003-09-16 CN CNA038250683A patent/CN1694720A/zh active Pending
- 2003-09-16 EP EP03752398A patent/EP1545587B1/en not_active Expired - Lifetime
- 2003-09-16 JP JP2004536558A patent/JP4516844B2/ja not_active Expired - Fee Related
- 2003-09-16 AT AT03752398T patent/ATE497778T1/de not_active IP Right Cessation
- 2003-09-16 DE DE60335997T patent/DE60335997D1/de not_active Expired - Lifetime
- 2003-09-16 ES ES03752398T patent/ES2358645T3/es not_active Expired - Lifetime
- 2003-09-16 EP EP10014943A patent/EP2298338B1/en not_active Expired - Lifetime
- 2003-09-16 WO PCT/US2003/029069 patent/WO2004024180A1/en not_active Ceased
-
2009
- 2009-03-12 US US12/403,250 patent/US8030272B2/en not_active Expired - Fee Related
- 2009-10-13 AU AU2009225309A patent/AU2009225309B2/en not_active Expired - Fee Related
-
2011
- 2011-09-08 US US13/227,871 patent/US8247373B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE60335997D1 (de) | 2011-03-24 |
| AU2009225309B2 (en) | 2012-06-14 |
| WO2004024180A1 (en) | 2004-03-25 |
| US20040142037A1 (en) | 2004-07-22 |
| AU2003270690A1 (en) | 2004-04-30 |
| ATE497778T1 (de) | 2011-02-15 |
| EP2298338A1 (en) | 2011-03-23 |
| JP2006503044A (ja) | 2006-01-26 |
| AU2009225309A1 (en) | 2009-11-05 |
| EP1545587B1 (en) | 2011-02-09 |
| AU2003270690B2 (en) | 2009-07-30 |
| JP4516844B2 (ja) | 2010-08-04 |
| CN1694720A (zh) | 2005-11-09 |
| CA2499014A1 (en) | 2004-03-25 |
| SI2298338T1 (sl) | 2012-11-30 |
| DK2298338T3 (da) | 2012-09-24 |
| ES2358645T3 (es) | 2011-05-12 |
| EP1545587A4 (en) | 2009-06-17 |
| SI1545587T1 (sl) | 2011-06-30 |
| US8030272B2 (en) | 2011-10-04 |
| US7524814B2 (en) | 2009-04-28 |
| EP2298338B1 (en) | 2012-08-22 |
| US8247373B2 (en) | 2012-08-21 |
| US20120010150A1 (en) | 2012-01-12 |
| EP1545587A1 (en) | 2005-06-29 |
| US20090253627A1 (en) | 2009-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1545587T3 (da) | Lactoferrinsammensætninger og fremgangsmåder til behandling af diabetiske sår | |
| DK1615952T3 (da) | Fremgangsmåder til behandling af betændelsestilstande med specifikke, til humant angiopoietin-2-bindende midler | |
| DE602004031134D1 (de) | Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa | |
| ATE515261T1 (de) | Zusammensetzungen zur behandlung von diabetes | |
| ATE486860T1 (de) | Phenothiazin-derivat zur wundheilung | |
| ATE376446T1 (de) | Verwendung von n-hydroxyalkyl-o-benzylchitosanen zur haarbehandlung | |
| DK1596880T3 (da) | Fremgangsmåder og sammensætninger til undertrykkelse af fibrocytdifferentiering | |
| DK1651161T3 (da) | Farmaceutiske præparater og fremgangsmåder til at fremme sårheling | |
| DE60332163D1 (de) | Zusammensetzung zur hautaufhellung | |
| DE60036169D1 (de) | Methoden zur Behandlung der Hautpigmentierung | |
| ATE489957T1 (de) | Mittel zur behandlung von entzündlichen erkrankungen | |
| DK1790354T3 (da) | Anvendelse af plasminogen til sårheling | |
| DE60112807D1 (de) | Zusammensetzung zur behandlung von durch arterielle irrigationsdefekt gewebeschäden | |
| DK1919466T3 (da) | Formuleringer til behandling af lipoprotein-abnormiteter omfattende et statin og et methylnicotinamidderivat | |
| DK1545548T3 (da) | Anvendelsen af kombinationen af ciclesonid og antihistaminer til behandingen af allergisk rhinitis | |
| NO20042012L (no) | Sammensetning og fremgangsmate for behandling av diabetes | |
| DE60206289D1 (de) | Verwendung von bibn4096 in kombination mit anderen migränemitteln zur behandlung von migräne | |
| DE602004029376D1 (de) | Fettzusammensetzung für backware, sowie backware | |
| EP1663283A4 (en) | GLUTAMINE FOR THE TREATMENT OF LESION | |
| DE60325496D1 (de) | Verwendung von dihydroimidazolonen zur behandlung von epilepsie bei hunden | |
| DE69920015D1 (de) | Verfahren zur induktion der herstellung von wachstumsfaktoren | |
| BRPI0411168A (pt) | composição para o tratamento dos cabelos, usos de uma composição e método de tratamento dos cabelos | |
| DK1523985T3 (da) | Ikke-radioaktivt strontiumholdigt middel til behandling af kræft | |
| ATE506069T1 (de) | Verfahren und zusammensetzung zur modulation des systemischen entzündlichen reaktionssyndroms (sirs) | |
| DE60219495D1 (de) | Verwendung von Interleukin-18 zur Behandlung von UV-assoziierten Hautkrankheiten |